Drug-Drug Interactions and Their Association With Quality of Life in Patients With Hypertension

被引:0
|
作者
Gurel, Nermin [1 ]
Uresin, Yagiz [2 ]
Sen, Selcuk [2 ]
机构
[1] Mehmet Akif Ersoy Thorac & Cardiovasc Surg Trainin, Good Clin Practice & Res Ctr, Pharmacol & Therapeut, Istanbul, Turkiye
[2] Istanbul Univ, Istanbul Fac Med, Div Clin Pharmacol, Med Pharmacol, Istanbul, Turkiye
关键词
body mass index; age; quality of life; drug interaction; antihypertensive; hypertension;
D O I
10.7759/cureus.56526
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction This study aimed to evaluate drug -drug interactions (DDIs) and their association with the quality of life in patients with hypertension. Materials and methods This cross-sectional study included 123 patients with hypertension. DDIs were evaluated using the Medscape Drug Interaction Checker Database (Medscape, New York, NY). The EuroQol-5D (EQ-5D) Quality of Life Scale was used for each patient. Results The overall blood pressure control rate (systolic/diastolic blood pressure levels, <140/90 mmHg) was 43% (53/123). The age of the patients with uncontrolled hypertension was higher than the patients with controlled hypertension (63.67 +/- 11.00 vs. 58.42 +/- 10.07 years; p = 0.007). The number of DDIs showed significant correlations, positively with age (r = 0.303, p = 0.001), total number of drugs (r = 0.784, p < 0.001), number of antihypertensive drugs (r = 0.640, p < 0.001), and body mass index (BMI) (r = 0.321, p < 0.001) and inversely with EQ-5D index score (r = -0.247, p = 0.006). The EQ-5D index and visual analog score were inversely correlated with age and BMI. Additional significant linear correlations between age and the total number of drugs, age and number of the antihypertensive drugs, the number of antihypertensive drugs and BMI, and the number of total drugs and BMI were detected. Of a total of 511 identified DDIs, 14 interactions in 12 patients were considered serious, 402 interactions in 82 patients were considered significant, and 95 interactions in 39 patients were considered minor. Conclusions This study supports that DDIs have important associations with antihypertensive treatment and the quality of life of patients. Higher age and BMI values were associated with a higher risk of DDIs and lower quality of life in patients with hypertension.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Incidence of potential drug-drug interactions with antidiabetic drugs
    Samardzic, I.
    Bacic-Vrca, V.
    PHARMAZIE, 2015, 70 (06): : 410 - 415
  • [22] Drug-drug interactions in medical patients:: Effects of in-hospital treatment and relation to multiple drug use
    Köhler, GI
    Bode-Böger, SM
    Busse, R
    Hoopmann, M
    Welte, T
    Böger, RH
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (11) : 504 - 513
  • [23] Drug-drug interactions involving new antiretroviral drugs and drug classes
    Soodalter, Jesse
    Sousa, Marta
    Boffito, Marta
    CURRENT OPINION IN INFECTIOUS DISEASES, 2009, 22 (01) : 18 - 27
  • [24] Observational study of drug-drug interactions in oncological inpatients
    Sacramento Diaz-Carrasco, Maria
    Almanchel-Rivadeneyra, Miguel
    Tomas-Luiz, Aina
    Pelegrin-Montesinos, Sandra
    Ramirez-Roig, Cristina
    Jose Fernandez-Avila, Juan
    FARMACIA HOSPITALARIA, 2018, 42 (01) : 10 - 15
  • [25] Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction
    Hanigan, Sarah
    Park, Jeong M.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (03) : 189 - 202
  • [26] Drug treatments and interactions, disease progression and quality of life in ALS patients
    Diamanti, Luca
    Bianchi, Elisa
    Mucaj, Klodjana
    Cereda, Cristina
    Garattini, Silvio
    Beghi, Ettore
    Pupillo, Elisabetta
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2022, 23 (5-6) : 415 - 423
  • [27] The prevalence of drug-drug interactions in cancer therapy and the clinical outcomes
    Alnaim, Lamya S.
    Almalki, Hind M.
    Almutairi, Afrah M.
    Salamah, Heba J.
    LIFE SCIENCES, 2022, 310
  • [28] Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
    Paul Hollywood
    Rachel MacCann
    David Lorigan
    Eoghan de Barra
    Samuel McConkey
    Irish Journal of Medical Science (1971 -), 2020, 189 : 693 - 699
  • [29] Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
    Hollywood, Paul
    MacCann, Rachel
    Lorigan, David
    de Barra, Eoghan
    McConkey, Samuel
    IRISH JOURNAL OF MEDICAL SCIENCE, 2020, 189 (02) : 693 - 699
  • [30] Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions
    Hauben, Manfred
    CLINICAL THERAPEUTICS, 2023, 45 (02) : 117 - 133